



NDA 22-332

NDA APPROVAL

Eli Lilly and Company
Attention: Dr. Gregory Brophy
Lilly Corporate Center
Indianapolis, IN 46285

Dear Dr. Brophy:

Please refer to your new drug application (NDA) dated July 23, 2008, received July 24, 2008, submitted under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act for Adcirca (tadalafil) 20 mg Tablets.

We acknowledge receipt of your submissions dated September 25, October 13 (two), November 17, December 22, 2008, and February 3, and March 2, 2009.

This new drug application provides for the use of Adcirca (tadalafil) 20 mg Tablets for the treatment of pulmonary arterial hypertension (WHO Group I) to improve exercise ability.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format as described at <http://www.fda.gov/oc/datacouncil/spl.html> that is identical to the enclosed agreed-upon labeling text. Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, "**SPL for approved NDA 22-332.**"

Submit the final printed container label that is identical to the enclosed immediate container label as soon as it is available, but no more than 30 days after it is printed. Please submit the label electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (October 2005)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission "**Final Printed Carton and Container Labels for approved NDA 22-332.**" Approval of this submission by FDA is not required before the label is used.

Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

PROPRIETARY NAME

The Division of Medication Error Prevention and Analysis (DMEPA) and the Division of Cardiovascular and Renal Products do not object to the use of the proprietary name, Adcirca, for this product.

PEDIATRIC RESEARCH EQUITY ACT (PREA)

The Pediatric Research Equity Act is not applicable to drugs granted orphan drug designation.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see www.fda.gov/cder/ddmac.

LETTERS TO HEALTH CARE PROFESSIONALS

If you issue a letter communicating important safety related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

MedWatch
Food and Drug Administration
Suite 12B05
5600 Fishers Lane
Rockville, MD 20857

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

NDA 22-332

Page 3

If you have any questions, please call Dan Brum, PharmD, MBA, RAC, Regulatory Project Manager, at (301) 796-0578.

Sincerely,

{See appended electronic signature page}

Norman Stockbridge, M.D., Ph.D.
Director
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure: Agreed-upon labeling text

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Norman Stockbridge
5/22/2009 03:04:53 PM